Cingulate Inc. (CINGW)
0.04
-0.00 (-11.11%)
At close: Mar 25, 2025, 3:16 PM
-11.11% (1D)
| Bid | 0.03 |
| Market Cap | 112.43K |
| Revenue (ttm) | -7B |
| Net Income (ttm) | -5.9B |
| EPS (ttm) | -1.732 |
| PE Ratio (ttm) | -0.02 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.04 |
| Volume | 24,415 |
| Avg. Volume (20D) | 62,451.281 |
| Open | 0.04 |
| Previous Close | 0.04 |
| Day's Range | 0.03 - 0.04 |
| 52-Week Range | 0.03 - 0.04 |
| Beta | -0.84 |
About CINGW
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was fo...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 13
Stock Exchange NASDAQ
Ticker Symbol CINGW
Website https://www.cingulate.com